• Leukemias, lymphomas, and other hematologic cancers

Thioguanine Generic Name & Formulations

General Description

Thioguanine 40mg; tabs; scored.

Pharmacological Class


How Supplied

Contact supplier.

Thioguanine Indications


Remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. Treatment of the chronic phase of chronic myelogenous leukemia (see full labeling).

Thioguanine Dosage and Administration

Adults and Children

See full labeling. Initially, 2mg/kg per day. If, after 4 weeks, with no improvement, no leukocyte or platelet depression, may increase to 3mg/kg per day. Total daily dose may be given at one time.

Thioguanine Contraindications


Allergy to mercaptopurine.

Thioguanine Boxed Warnings

Not Applicable

Thioguanine Warnings/Precautions


Not recommended for maintenance therapy or long-term continuous treatments; increased risk of liver toxicity (discontinue if occurs). Pre-existing liver disease. Monitor liver function tests weekly at start of therapy, then monthly thereafter. Thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency (may need to reduce dose to avoid severe bone marrow suppression); consider testing for TPMT and NUDT15 deficiency. Obtain hemoglobin, hematocrit, WBCs with differential, platelets frequently during therapy. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Thioguanine Pharmacokinetics

See Literature

Thioguanine Interactions


Avoid live vaccines (if immunocompromised). Caution with drugs that inhibit TPMT (eg, olsalazine, mesalazine, or sulphasalazine).

Thioguanine Adverse Reactions

Adverse Reactions

Myelosuppression, hyperuricemia, GI upset, anorexia, stomatitis, hepatotoxicity, elevated liver enzymes, jaundice (discontinue if occurs).

Thioguanine Clinical Trials

See Literature

Thioguanine Note


Formerly known under the brand name Tabloid.

Thioguanine Patient Counseling

See Literature